Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 10

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 10
---
 500,000  
     - 
  
    Proceeds received from sale of Series C Preferred Stock, net of issuance costs of $434,428 
     -  
     703,964  

    Proceeds received from sale of Series D Preferred Stock 
     2,560,981  
     -  
     - 
  
    Proceeds received from sale of common stock and warrants 
     588,000  
     -  
     - 
  
    Proceeds received from sale of pre-funded warrants, net of issuance costs 
     3,685,027  
     -  
     - 
  
    Payment of deferred offering costs 
     (174,505) 
     -  
     - 
  
    Proceeds from exercise of pre-funded warrants 
     203  
     -  
     - 
  
    Cash redemption of Series C Preferred Stock 
     (395,000) 
     -  
     - 
  
    Net cash provided by financing activities 
     10,468,829  
     12,240,682  
     - 

    Net increase (decrease) in cash, restricted cash and cash equivalents 
     (1,304,988) 
     1,502,209  
     (637,400)

    Cash, restricted cash and cash equivalents at beginning of period 
     3,327,060  
     1,877,995  
     1,601,255 

    Cash, restricted cash and cash equivalents at end of period 
    $2,022,072  
    $3,380,204  
    $963,855 

    SUPPLEMENTAL CASH FLOW INFORMATION: 

    Cash and cash equivalents 
    $1,947,316  
    $3,300,448  
    $884,099 
  
    Restricted cash 
     74,756  
     79,756  
     79,756 
  
    Cash, restricted cash and cash equivalents 
    $2,022,072  
    $3,380,204  
    $963,855 

    NON-CASH FINANCING ACTIVITIES: 

    Issuance of common shares to Keystone Capital LLC for equity line of credit 
    $-  
    $500,000